Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

NAVEEN GARA

Allopathic & Osteopathic Physicians Internal Medicine Gastroenterology

NPI
1942406533
CMS profile
1158997
Location
SAN DIEGO, CA

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2022 · Entire year

$55,378.58

117 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2022 · entire year · sorted by reported total

By paying entity

PY2022 · entire year · sorted by reported total

Page 2 of 3; records 51–100 of 117 matching records. This page contains 50 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

NAVEEN GARA

NPI 1942406533 · CMS profile ID 1158997

Allopathic & Osteopathic Physicians / Internal Medicine / Gastroenterology

SAN DIEGO, CA

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 2 of 3; records 51–100 of 117 matching records. This page contains 50 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1942406533?year=2022&recipient=provider&page=2#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
NAVEEN GARA, NPI 1942406533, CMS profile ID 1158997. General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 3; records 51–100 of 117 matching records. This page contains 50 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1942406533?year=2022&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c.
APA 7
IndustryPayments. (2026). NAVEEN GARA, NPI 1942406533, CMS profile ID 1158997. General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 3; records 51–100 of 117 matching records. This page contains 50 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1942406533?year=2022&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c.
Bluebook
NAVEEN GARA, NPI 1942406533, CMS profile ID 1158997, IndustryPayments, General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 2 of 3; records 51–100 of 117 matching records. This page contains 50 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c. https://industrypayments.org/provider/npi-1942406533?year=2022&recipient=provider&page=2#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2022

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2022 · Physicians and non-physician practitioners · CMS publication 2026-06-30

117 matching records · $55,378.58 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 117 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 51–100 of 117.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
ABBVIE INC. $23.1508/17/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 891003421 CMS
Medtronic, Inc. $267.4708/17/2022 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 933656249 CMS
Medtronic, Inc. $30.0008/17/2022 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 933656251 CMS
PENTAX of America, Inc. $17.6408/12/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 918300273 CMS
ABBVIE INC. $20.0808/10/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 891003419 CMS
ABBVIE INC. $74.4608/08/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 891003417 CMS
Medtronic, Inc. $650.0008/08/2022 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 910004935 CMS
Janssen Biotech, Inc. $5.9207/21/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 885580427 CMS
Medtronic, Inc. $1,075.0007/21/2022 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 910004973 CMS
Takeda Pharmaceuticals U.S.A., Inc. $21.3607/14/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 955640365 CMS
ABBVIE INC. $28.5307/13/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 891003415 CMS
Takeda Pharmaceuticals U.S.A., Inc. $13.6907/13/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 955640363 CMS
ABBVIE INC. $2,025.0007/11/2022 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 891003413 CMS
Janssen Biotech, Inc. $17.2406/30/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 885580415 CMS
Gilead Sciences, Inc. $18.5006/28/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 929583501 CMS
Takeda Pharmaceuticals U.S.A., Inc. $14.5306/28/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 955640361 CMS
ABBVIE INC. $5,400.0006/24/2022 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 891003411 CMS
ABBVIE INC. $26.9506/22/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 891003409 CMS
ABBVIE INC. $431.5806/18/2022 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 891003387 CMS
ABBVIE INC. $294.0106/18/2022 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 891003389 CMS
ABBVIE INC. $224.4006/18/2022 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 891003391 CMS
ABBVIE INC. $18.5706/18/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 891003393 CMS
ABBVIE INC. $40.0006/18/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 891003395 CMS
ABBVIE INC. $18.5606/18/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 891003397 CMS
ABBVIE INC. $30.0006/18/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 891003399 CMS
ABBVIE INC. $18.5606/18/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 891003401 CMS
ABBVIE INC. $65.0006/18/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 891003403 CMS
ABBVIE INC. $18.5606/18/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 891003405 CMS
ABBVIE INC. $30.0006/18/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 891003407 CMS
ABBVIE INC. $224.4006/17/2022 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 891003385 CMS
Boston Scientific Corporation $24.4606/14/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 916554333 CMS
Medtronic, Inc. $650.0006/09/2022 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 910004967 CMS
ABBVIE INC. $28.3306/08/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 891003383 CMS
Janssen Biotech, Inc. $6.2006/06/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 885580419 CMS
RedHill Biopharma Inc. $17.4006/01/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 902947409 CMS
ABBVIE INC. $21.3205/26/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 891003381 CMS
ABBVIE INC. $23.3205/18/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 891003379 CMS
Gilead Sciences, Inc. $15.5305/11/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 929583493 CMS
ABBVIE INC. $3,375.0005/09/2022 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 891003377 CMS
ABBVIE INC. $18.0405/03/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 891003375 CMS
Medtronic, Inc. $2,300.0004/28/2022 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 910004963 CMS
Gilead Sciences, Inc. $18.3504/27/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 929583499 CMS
Ferring Pharmaceuticals Inc. $17.1304/20/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 875349309 CMS
Janssen Biotech, Inc. $30.6804/17/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 885580449 CMS
ABBVIE INC. $26.3704/14/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 891003373 CMS
ABBVIE INC. $28.1404/06/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 891003371 CMS
Gilead Sciences, Inc. $17.8703/24/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 929583497 CMS
ABBVIE INC. $24.5903/22/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 891003369 CMS
ABBVIE INC. $25.9403/16/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 891003367 CMS
Medtronic, Inc. $8,350.0003/16/2022 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 910004957 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $28,125.14 47
PY2020 $555.07 26
PY2021 $24,562.06 60
PY2022 $55,378.58 117
PY2023 $9,053.10 75
PY2024 $39,008.53 111
PY2025 $21,443.05 105

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $356,915.90 58
PY2024 Principal investigator $473,065.13 176
PY2023 Principal investigator $453,902.15 44
PY2022 Recipient $27,300.00 2
PY2022 Principal investigator $61,427.19 3

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

58 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 SANOFI US SERVICES INC. $1,600.00 12/24/2025 Non-covered Recipient Entity
Gastroenterology And Liver Institute
A Phase 2, Multicenter, Randomized, Double-blind, Placebo Controlled, Dose-ranging Study to Evaluate the Efficacy and Safety of SAR442970 in Adults With Moderate to Severe Crohn's Disease No dispute reported 06/30/2026 1226098148
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $1,327.00 12/17/2025 Non-covered Recipient Entity
GASTROENTEROLOGY AND LIVER INSTITUTE
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 2 DOSE-RANGING STUDY TO EVALUATE THE EFFICACY AND SAFETY OF TAK-101 FOR THE PREVENTION OF GLUTEN-SPECIFIC T CELL ACTIVATION IN SUBJECTS WITH CELIAC DISEASE ON A GLUTEN-FREE DIET No dispute reported 06/30/2026 1223289734
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $5,499.00 12/17/2025 Non-covered Recipient Entity
GASTROENTEROLOGY AND LIVER INSTITUTE
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 2 DOSE-RANGING STUDY TO EVALUATE THE EFFICACY AND SAFETY OF TAK-101 FOR THE PREVENTION OF GLUTEN-SPECIFIC T CELL ACTIVATION IN SUBJECTS WITH CELIAC DISEASE ON A GLUTEN-FREE DIET No dispute reported 06/30/2026 1223289736
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $663.00 12/17/2025 Non-covered Recipient Entity
GASTROENTEROLOGY AND LIVER INSTITUTE
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 2 DOSE-RANGING STUDY TO EVALUATE THE EFFICACY AND SAFETY OF TAK-101 FOR THE PREVENTION OF GLUTEN-SPECIFIC T CELL ACTIVATION IN SUBJECTS WITH CELIAC DISEASE ON A GLUTEN-FREE DIET No dispute reported 06/30/2026 1223289738
Principal investigator 1 SANOFI US SERVICES INC. $10,943.00 12/12/2025 Non-covered Recipient Entity
Gastroenterology And Liver Institute
A Phase 2, Multicenter, Randomized, Double-blind, Placebo Controlled, Dose-ranging Study to Evaluate the Efficacy and Safety of SAR442970 in Adults With Moderate to Severe Crohn's Disease No dispute reported 06/30/2026 1226098133
Principal investigator 1 SANOFI US SERVICES INC. $2,083.00 12/12/2025 Non-covered Recipient Entity
Gastroenterology And Liver Institute
A Phase 2, Multicenter, Randomized, Double-blind, Placebo Controlled, Dose-ranging Study to Evaluate the Efficacy and Safety of SAR442970 in Adults With Moderate to Severe Crohn's Disease No dispute reported 06/30/2026 1226098141
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $1,350.00 11/17/2025 Non-covered Recipient Entity
GASTROENTEROLOGY AND LIVER INSTITUTE
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 2 DOSE-RANGING STUDY TO EVALUATE THE EFFICACY AND SAFETY OF TAK-101 FOR THE PREVENTION OF GLUTEN-SPECIFIC T CELL ACTIVATION IN SUBJECTS WITH CELIAC DISEASE ON A GLUTEN-FREE DIET No dispute reported 06/30/2026 1223288363
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $4,800.00 11/17/2025 Non-covered Recipient Entity
GASTROENTEROLOGY AND LIVER INSTITUTE
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 2 DOSE-RANGING STUDY TO EVALUATE THE EFFICACY AND SAFETY OF TAK-101 FOR THE PREVENTION OF GLUTEN-SPECIFIC T CELL ACTIVATION IN SUBJECTS WITH CELIAC DISEASE ON A GLUTEN-FREE DIET No dispute reported 06/30/2026 1223288365
Principal investigator 1 SANOFI US SERVICES INC. $11,747.00 11/05/2025 Non-covered Recipient Entity
Gastroenterology And Liver Institute
A Phase 2b, Multi-national, Multi-center, Randomized, Double-blind, Placebo-controlled, Dose-ranging Study Followed by a Long-term Extension to Evaluate the Efficacy and Safety of SAR442970 in Adult Participants With Moderate to Severe Ulcerative Colitis No dispute reported 06/30/2026 1226098183
Principal investigator 1 SANOFI US SERVICES INC. $3,519.00 11/05/2025 Non-covered Recipient Entity
Gastroenterology And Liver Institute
A Phase 2b, Multi-national, Multi-center, Randomized, Double-blind, Placebo-controlled, Dose-ranging Study Followed by a Long-term Extension to Evaluate the Efficacy and Safety of SAR442970 in Adult Participants With Moderate to Severe Ulcerative Colitis No dispute reported 06/30/2026 1226098190
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $675.00 11/03/2025 Non-covered Recipient Entity
GASTROENTEROLOGY AND LIVER INSTITUTE
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 2 DOSE-RANGING STUDY TO EVALUATE THE EFFICACY AND SAFETY OF TAK-101 FOR THE PREVENTION OF GLUTEN-SPECIFIC T CELL ACTIVATION IN SUBJECTS WITH CELIAC DISEASE ON A GLUTEN-FREE DIET No dispute reported 06/30/2026 1223287843
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $1,200.00 11/03/2025 Non-covered Recipient Entity
GASTROENTEROLOGY AND LIVER INSTITUTE
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 2 DOSE-RANGING STUDY TO EVALUATE THE EFFICACY AND SAFETY OF TAK-101 FOR THE PREVENTION OF GLUTEN-SPECIFIC T CELL ACTIVATION IN SUBJECTS WITH CELIAC DISEASE ON A GLUTEN-FREE DIET No dispute reported 06/30/2026 1223287845
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $1,327.00 10/15/2025 Non-covered Recipient Entity
GASTROENTEROLOGY AND LIVER INSTITUTE
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 2 DOSE-RANGING STUDY TO EVALUATE THE EFFICACY AND SAFETY OF TAK-101 FOR THE PREVENTION OF GLUTEN-SPECIFIC T CELL ACTIVATION IN SUBJECTS WITH CELIAC DISEASE ON A GLUTEN-FREE DIET No dispute reported 06/30/2026 1223286845
Principal investigator 1 Bausch Health US, LLC $4,714.13 09/24/2025 Non-covered Recipient Entity
Gastroenterology & Liver Institute
A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Assess the Efficacy and Safety of Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis No dispute reported 06/30/2026 1224841002
Principal investigator 1 AstraZeneca UK Limited $41,505.60 09/17/2025 Non-covered Recipient Entity
GASTROENTEROLOGY AND LIVER INSTITUTE
A Double-blind, Placebo-controlled Phase IIa Study to Evaluate the Efficacy and Safety of AZD7798 in Patients with Moderate to Severe Crohns Disease AMALTHEA No dispute reported 06/30/2026 1185547481
Principal investigator 1 Bausch Health US, LLC $12,371.26 09/11/2025 Non-covered Recipient Entity
Gastroenterology & Liver Institute
A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Assess the Efficacy and Safety of Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis No dispute reported 06/30/2026 1224841006
Principal investigator 1 SANOFI US SERVICES INC. $32,279.00 09/10/2025 Non-covered Recipient Entity
Gastroenterology And Liver Institute
A Phase 2b, Multi-national, Multi-center, Randomized, Double-blind, Placebo-controlled, Dose-ranging Study Followed by a Long-term Extension to Evaluate the Efficacy and Safety of SAR442970 in Adult Participants With Moderate to Severe Ulcerative Colitis No dispute reported 06/30/2026 1226097995
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $750.00 09/10/2025 Non-covered Recipient Entity
GASTROENTEROLOGY AND LIVER INSTITUTE
A Study of Vedolizumab in Adults With Ulcerative Colitis or Crohn's Disease in the Community Setting (PANORAMA) No dispute reported 06/30/2026 1223285179
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $2,300.00 09/10/2025 Non-covered Recipient Entity
GASTROENTEROLOGY AND LIVER INSTITUTE
A Study of Vedolizumab in Adults With Ulcerative Colitis or Crohn's Disease in the Community Setting (PANORAMA) No dispute reported 06/30/2026 1223285181
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $15,000.00 09/10/2025 Non-covered Recipient Entity
GASTROENTEROLOGY AND LIVER INSTITUTE
A Study of Vedolizumab in Adults With Ulcerative Colitis or Crohn's Disease in the Community Setting (PANORAMA) No dispute reported 06/30/2026 1223285183
Principal investigator 1 SANOFI US SERVICES INC. $26,510.00 08/20/2025 Non-covered Recipient Entity
Gastroenterology And Liver Institute
A Phase 2, Multicenter, Randomized, Double-blind, Placebo Controlled, Dose-ranging Study to Evaluate the Efficacy and Safety of SAR442970 in Adults With Moderate to Severe Crohn's Disease No dispute reported 06/30/2026 1226098018
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $1,354.00 08/11/2025 Non-covered Recipient Entity
GASTROENTEROLOGY AND LIVER INSTITUTE
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 2 DOSE-RANGING STUDY TO EVALUATE THE EFFICACY AND SAFETY OF TAK-101 FOR THE PREVENTION OF GLUTEN-SPECIFIC T CELL ACTIVATION IN SUBJECTS WITH CELIAC DISEASE ON A GLUTEN-FREE DIET No dispute reported 06/30/2026 1223284063
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $1,226.00 08/11/2025 Non-covered Recipient Entity
GASTROENTEROLOGY AND LIVER INSTITUTE
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 2 DOSE-RANGING STUDY TO EVALUATE THE EFFICACY AND SAFETY OF TAK-101 FOR THE PREVENTION OF GLUTEN-SPECIFIC T CELL ACTIVATION IN SUBJECTS WITH CELIAC DISEASE ON A GLUTEN-FREE DIET No dispute reported 06/30/2026 1223284065
Principal investigator 1 Bausch Health US, LLC $6,144.45 08/08/2025 Non-covered Recipient Entity
Gastroenterology & Liver Institute
A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Assess the Efficacy and Safety of Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis No dispute reported 06/30/2026 1224840997
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $1,000.00 07/28/2025 Non-covered Recipient Entity
GASTROENTEROLOGY AND LIVER INSTITUTE
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 2 DOSE-RANGING STUDY TO EVALUATE THE EFFICACY AND SAFETY OF TAK-101 FOR THE PREVENTION OF GLUTEN-SPECIFIC T CELL ACTIVATION IN SUBJECTS WITH CELIAC DISEASE ON A GLUTEN-FREE DIET No dispute reported 06/30/2026 1223283250
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $617.61 07/28/2025 Non-covered Recipient Entity
GASTROENTEROLOGY AND LIVER INSTITUTE
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 2 DOSE-RANGING STUDY TO EVALUATE THE EFFICACY AND SAFETY OF TAK-101 FOR THE PREVENTION OF GLUTEN-SPECIFIC T CELL ACTIVATION IN SUBJECTS WITH CELIAC DISEASE ON A GLUTEN-FREE DIET No dispute reported 06/30/2026 1223283252
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $1,500.00 07/28/2025 Non-covered Recipient Entity
GASTROENTEROLOGY AND LIVER INSTITUTE
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 2 DOSE-RANGING STUDY TO EVALUATE THE EFFICACY AND SAFETY OF TAK-101 FOR THE PREVENTION OF GLUTEN-SPECIFIC T CELL ACTIVATION IN SUBJECTS WITH CELIAC DISEASE ON A GLUTEN-FREE DIET No dispute reported 06/30/2026 1223283254
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $663.00 07/16/2025 Non-covered Recipient Entity
GASTROENTEROLOGY AND LIVER INSTITUTE
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 2 DOSE-RANGING STUDY TO EVALUATE THE EFFICACY AND SAFETY OF TAK-101 FOR THE PREVENTION OF GLUTEN-SPECIFIC T CELL ACTIVATION IN SUBJECTS WITH CELIAC DISEASE ON A GLUTEN-FREE DIET No dispute reported 06/30/2026 1223282638
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $1,558.00 07/16/2025 Non-covered Recipient Entity
GASTROENTEROLOGY AND LIVER INSTITUTE
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 2 DOSE-RANGING STUDY TO EVALUATE THE EFFICACY AND SAFETY OF TAK-101 FOR THE PREVENTION OF GLUTEN-SPECIFIC T CELL ACTIVATION IN SUBJECTS WITH CELIAC DISEASE ON A GLUTEN-FREE DIET No dispute reported 06/30/2026 1223282640
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $200.00 07/11/2025 Non-covered Recipient Entity
GASTROENTEROLOGY AND LIVER INSTITUTE
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 2 DOSE-RANGING STUDY TO EVALUATE THE EFFICACY AND SAFETY OF TAK-101 FOR THE PREVENTION OF GLUTEN-SPECIFIC T CELL ACTIVATION IN SUBJECTS WITH CELIAC DISEASE ON A GLUTEN-FREE DIET No dispute reported 06/30/2026 1223282540
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $675.00 07/11/2025 Non-covered Recipient Entity
GASTROENTEROLOGY AND LIVER INSTITUTE
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 2 DOSE-RANGING STUDY TO EVALUATE THE EFFICACY AND SAFETY OF TAK-101 FOR THE PREVENTION OF GLUTEN-SPECIFIC T CELL ACTIVATION IN SUBJECTS WITH CELIAC DISEASE ON A GLUTEN-FREE DIET No dispute reported 06/30/2026 1223282542
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $1,200.00 07/11/2025 Non-covered Recipient Entity
GASTROENTEROLOGY AND LIVER INSTITUTE
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 2 DOSE-RANGING STUDY TO EVALUATE THE EFFICACY AND SAFETY OF TAK-101 FOR THE PREVENTION OF GLUTEN-SPECIFIC T CELL ACTIVATION IN SUBJECTS WITH CELIAC DISEASE ON A GLUTEN-FREE DIET No dispute reported 06/30/2026 1223282544
Principal investigator 1 Bausch Health US, LLC $6,164.97 07/09/2025 Non-covered Recipient Entity
Gastroenterology & Liver Institute
A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Assess the Efficacy and Safety of Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis No dispute reported 06/30/2026 1224841010
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $2,849.00 06/18/2025 Non-covered Recipient Entity
GASTROENTEROLOGY AND LIVER INSTITUTE
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 2 DOSE-RANGING STUDY TO EVALUATE THE EFFICACY AND SAFETY OF TAK-101 FOR THE PREVENTION OF GLUTEN-SPECIFIC T CELL ACTIVATION IN SUBJECTS WITH CELIAC DISEASE ON A GLUTEN-FREE DIET No dispute reported 06/30/2026 1223281538
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $951.00 06/18/2025 Non-covered Recipient Entity
GASTROENTEROLOGY AND LIVER INSTITUTE
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 2 DOSE-RANGING STUDY TO EVALUATE THE EFFICACY AND SAFETY OF TAK-101 FOR THE PREVENTION OF GLUTEN-SPECIFIC T CELL ACTIVATION IN SUBJECTS WITH CELIAC DISEASE ON A GLUTEN-FREE DIET No dispute reported 06/30/2026 1223281540
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $5,683.00 06/18/2025 Non-covered Recipient Entity
GASTROENTEROLOGY AND LIVER INSTITUTE
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 2 DOSE-RANGING STUDY TO EVALUATE THE EFFICACY AND SAFETY OF TAK-101 FOR THE PREVENTION OF GLUTEN-SPECIFIC T CELL ACTIVATION IN SUBJECTS WITH CELIAC DISEASE ON A GLUTEN-FREE DIET No dispute reported 06/30/2026 1223281542
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $852.00 06/18/2025 Non-covered Recipient Entity
GASTROENTEROLOGY AND LIVER INSTITUTE
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 2 DOSE-RANGING STUDY TO EVALUATE THE EFFICACY AND SAFETY OF TAK-101 FOR THE PREVENTION OF GLUTEN-SPECIFIC T CELL ACTIVATION IN SUBJECTS WITH CELIAC DISEASE ON A GLUTEN-FREE DIET No dispute reported 06/30/2026 1223281544
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $5,499.00 06/18/2025 Non-covered Recipient Entity
GASTROENTEROLOGY AND LIVER INSTITUTE
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 2 DOSE-RANGING STUDY TO EVALUATE THE EFFICACY AND SAFETY OF TAK-101 FOR THE PREVENTION OF GLUTEN-SPECIFIC T CELL ACTIVATION IN SUBJECTS WITH CELIAC DISEASE ON A GLUTEN-FREE DIET No dispute reported 06/30/2026 1223281546
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $27.00 06/13/2025 Non-covered Recipient Entity
GASTROENTEROLOGY AND LIVER INSTITUTE
A STUDY OF TAK-062 IN TREATMENT OF ACTIVE CELIAC DISEASE IN PARTICIPANTS ATTEMPTING A GLUTEN-FREE DIET No dispute reported 06/30/2026 1223281186
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $23,320.00 06/13/2025 Non-covered Recipient Entity
GASTROENTEROLOGY AND LIVER INSTITUTE
A STUDY OF TAK-062 IN TREATMENT OF ACTIVE CELIAC DISEASE IN PARTICIPANTS ATTEMPTING A GLUTEN-FREE DIET No dispute reported 06/30/2026 1223281188
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $22,862.70 06/13/2025 Non-covered Recipient Entity
GASTROENTEROLOGY AND LIVER INSTITUTE
A STUDY OF TAK-062 IN TREATMENT OF ACTIVE CELIAC DISEASE IN PARTICIPANTS ATTEMPTING A GLUTEN-FREE DIET No dispute reported 06/30/2026 1223281190
Principal investigator 1 Bausch Health US, LLC $26,908.78 06/11/2025 Non-covered Recipient Entity
Gastroenterology & Liver Institute
A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Assess the Efficacy and Safety of Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis No dispute reported 06/30/2026 1224841034
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $2,849.00 05/14/2025 Non-covered Recipient Entity
GASTROENTEROLOGY AND LIVER INSTITUTE
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 2 DOSE-RANGING STUDY TO EVALUATE THE EFFICACY AND SAFETY OF TAK-101 FOR THE PREVENTION OF GLUTEN-SPECIFIC T CELL ACTIVATION IN SUBJECTS WITH CELIAC DISEASE ON A GLUTEN-FREE DIET No dispute reported 06/30/2026 1223279568
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $2,849.00 05/14/2025 Non-covered Recipient Entity
GASTROENTEROLOGY AND LIVER INSTITUTE
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 2 DOSE-RANGING STUDY TO EVALUATE THE EFFICACY AND SAFETY OF TAK-101 FOR THE PREVENTION OF GLUTEN-SPECIFIC T CELL ACTIVATION IN SUBJECTS WITH CELIAC DISEASE ON A GLUTEN-FREE DIET No dispute reported 06/30/2026 1223279570
Principal investigator 1 Bausch Health US, LLC $8,028.74 05/07/2025 Non-covered Recipient Entity
Gastroenterology & Liver Institute
A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Assess the Efficacy and Safety of Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis No dispute reported 06/30/2026 1224841040
Principal investigator 1 Bausch Health US, LLC $1,957.37 04/07/2025 Non-covered Recipient Entity
Gastroenterology & Liver Institute
A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Assess the Efficacy and Safety of Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis No dispute reported 06/30/2026 1224841037
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $3,000.00 04/02/2025 Non-covered Recipient Entity
GASTROENTEROLOGY AND LIVER INSTITUTE
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 2 DOSE-RANGING STUDY TO EVALUATE THE EFFICACY AND SAFETY OF TAK-101 FOR THE PREVENTION OF GLUTEN-SPECIFIC T CELL ACTIVATION IN SUBJECTS WITH CELIAC DISEASE ON A GLUTEN-FREE DIET No dispute reported 06/30/2026 1223277452
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $2,000.00 04/02/2025 Non-covered Recipient Entity
GASTROENTEROLOGY AND LIVER INSTITUTE
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 2 DOSE-RANGING STUDY TO EVALUATE THE EFFICACY AND SAFETY OF TAK-101 FOR THE PREVENTION OF GLUTEN-SPECIFIC T CELL ACTIVATION IN SUBJECTS WITH CELIAC DISEASE ON A GLUTEN-FREE DIET No dispute reported 06/30/2026 1223277454
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $2,700.00 04/02/2025 Non-covered Recipient Entity
GASTROENTEROLOGY AND LIVER INSTITUTE
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 2 DOSE-RANGING STUDY TO EVALUATE THE EFFICACY AND SAFETY OF TAK-101 FOR THE PREVENTION OF GLUTEN-SPECIFIC T CELL ACTIVATION IN SUBJECTS WITH CELIAC DISEASE ON A GLUTEN-FREE DIET No dispute reported 06/30/2026 1223277456
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $3,000.00 04/02/2025 Non-covered Recipient Entity
GASTROENTEROLOGY AND LIVER INSTITUTE
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 2 DOSE-RANGING STUDY TO EVALUATE THE EFFICACY AND SAFETY OF TAK-101 FOR THE PREVENTION OF GLUTEN-SPECIFIC T CELL ACTIVATION IN SUBJECTS WITH CELIAC DISEASE ON A GLUTEN-FREE DIET No dispute reported 06/30/2026 1223277458
Principal investigator 1 Bausch Health US, LLC $2,943.00 04/01/2025 Non-covered Recipient Entity
Gastroenterology & Liver Institute
A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Assess the Efficacy and Safety of Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis No dispute reported 06/30/2026 1224841030
Principal investigator 1 Bausch Health US, LLC $9,915.66 03/11/2025 Non-covered Recipient Entity
Gastroenterology & Liver Institute
A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Assess the Efficacy and Safety of Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis No dispute reported 06/30/2026 1224841022
Principal investigator 1 Bausch Health US, LLC $5,979.03 03/05/2025 Non-covered Recipient Entity
Gastroenterology & Liver Institute
A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Assess the Efficacy and Safety of Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis No dispute reported 06/30/2026 1224841026
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $3,000.00 02/12/2025 Non-covered Recipient Entity
GASTROENTEROLOGY AND LIVER INSTITUTE
A STUDY OF TAK-062 IN TREATMENT OF ACTIVE CELIAC DISEASE IN PARTICIPANTS ATTEMPTING A GLUTEN-FREE DIET No dispute reported 06/30/2026 1223275059
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $4,000.00 02/12/2025 Non-covered Recipient Entity
GASTROENTEROLOGY AND LIVER INSTITUTE
A STUDY OF TAK-062 IN TREATMENT OF ACTIVE CELIAC DISEASE IN PARTICIPANTS ATTEMPTING A GLUTEN-FREE DIET No dispute reported 06/30/2026 1223275061
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $1,500.00 02/12/2025 Non-covered Recipient Entity
GASTROENTEROLOGY AND LIVER INSTITUTE
A STUDY OF TAK-062 IN TREATMENT OF ACTIVE CELIAC DISEASE IN PARTICIPANTS ATTEMPTING A GLUTEN-FREE DIET No dispute reported 06/30/2026 1223275063
Principal investigator 1 Bausch Health US, LLC $2,467.98 01/28/2025 Non-covered Recipient Entity
Gastroenterology & Liver Institute
A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Assess the Efficacy and Safety of Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis No dispute reported 06/30/2026 1224841014
Principal investigator 1 Bausch Health US, LLC $7,307.62 01/07/2025 Non-covered Recipient Entity
Gastroenterology & Liver Institute
A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Assess the Efficacy and Safety of Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis No dispute reported 06/30/2026 1224841018